Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406274 · ClinicalTrials.gov registry record · NA
Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 249
- Enrollment target
NCT02406274: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02406274 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 249 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02406274, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 249 participants
- Enrollment target
Study Summary
Contrast Enhanced Spectral Mammography (CESM) is an advanced form of mammography which is performed after injection of contrast or dye into a vein in the arm. This dye is the same dye that is used for CT scans. This type of mammogram includes a regular mammogram as well as additional pictures with the dye. This particular study is being done to determine if by adding the dye in the veins the investigators are better able to identify the cause of the lump than if they just did the regular mammogram alone.
Interventions
- OTHER Contrast Enhanced Spectral Mammography (CESM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2015-03 |
| Est. Completion | 2024-06-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02406274
The ClinicalTrials.gov registry entry for NCT02406274 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Contrast Enhanced Spectral Mammography (CESM) is the first listed.
NCT02406274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02406274 about?
NCT02406274 is a clinical study titled "Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities". Contrast Enhanced Spectral Mammography (CESM) is an advanced form of mammography which is performed after injection of contrast or dye into a vein in the arm. This dye is the same dye that is used for CT scans. This type of mammogram includes a regular mammogram as well as additional pictures with t...
What is the current status of trial NCT02406274?
This trial is currently completed. It is a NA study. The enrollment target is 249 participants. The study started on 2015-03. Estimated completion is 2024-06-27.
What interventions are being tested in trial NCT02406274?
The interventions under investigation include: Contrast Enhanced Spectral Mammography (CESM) (OTHER).
Who is sponsoring clinical trial NCT02406274?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.